# K141311: 0.9% Sodium Chloride Injection, Usp BD Posiflush; SP Syringe, SF Syringe

- Pathway: 510(k) (Special)
- Applicant: Becton, Dickinson and Company
- Decided: Jul 25, 2014 after 66 days
- Product code: NGT (Saline, Vascular Access Flush)
- Device class: 2
- Regulation: 21 CFR 880.5200
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 3 generations back to K003553 (2001). 3 ancestors in all.
3 later devices descend from it; 1 cites it directly.
0 of 7 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- K121050: 0.9% Sodium Chloride Injection Usp BD Posiflush Flush Syringe, SF Flush Syringe, Becton, Dickinson & CO (2013) Summary page 1.

## Most influential descendants
- K161552: 0.9% Sodium Chloride Injection, USP BD PosiFlush SP Syringe (2017), 2 descendants of its own
- K250884: 0.9 % Sodium Chloride Injection, USP, BD PosiFlush™ SP Syringe (2025), 0 descendants of its own
- K213955: 0.9% Sodium Chloride Injection, USP, BD PosiFlush SafeScrub (2022), 0 descendants of its own

## Indications for use
The 0.9% Sodium Chloride Injection, USP, BD PosiFlush SP Syringes and 0.9% Sodium Chloride Injection, USP, BD PosiFlush SF Syringes are intended to be used only for the flushing of indwelling vascular access devices, Catalog Number 306547 10 mL 0.9% Sodium Chloride Injection, USP, BD PosiFlush SP Syringes are generally compatible for use with syringe pumps.

Source page: https://510kreport.com/device/K141311
Methodology: https://510kreport.com/methodology